Skip to main content
. 2022 Jul 25;61(10):1457–1469. doi: 10.1007/s40262-022-01147-w

Table 4.

Incidence of pulmonary exacerbations and post-baseline neutrophil elastase BLQ by brensocatib exposure

n/N (%) Placebo AUCτ quartile range
Q1
624–1758 ng·h/mL		 Q2
1813–2753 ng·h/mL		 Q3
2840–4824 ng·h/mL		 Q4
4845–10,562 ng·h/mL
Pulmonary exacerbations 42/84 (50.0) 12/40 (30.0) 14/39 (35.9) 16/39 (41.0) 12/39 (30.8)
624–1758 ng·h/mL 1813–2753 ng·h/mL 2840–4824 ng·h/mL 4845–9466 ng·h/mL
Sputum neutrophil elastase < BLQ 41/82 (50.0) 31/40 (77.5) 28/39 (71.8) 27/38 (71.1) 33/38 (86.8)

AUCτ area under the plasma concentration-time curve from time 0 to 24 h, BLQ below the level of quantification, Q quartile